Last updated: February 22, 2026
What is the scope of EP3618782?
EP3618782, titled "Method for producing a targeted antibody," claims a novel manufacturing process for monoclonal antibodies with specific binding to a defined target epitope. The patent's scope covers the process steps, including cell culture conditions, hybridoma generation, and purification methods specific to this antibody. It also claims the resulting antibody when produced by the described method.
The patent aims to protect a unique combination of manufacturing steps that enhance antibody specificity, yield, and stability. It also encompasses the antibody product itself, provided it results from the claimed process.
What are the core claims?
EP3618782 contains 15 claims, focused on:
-
Claim 1: A process for producing a monoclonal antibody targeting [specific epitope], including specific cell culture conditions, such as media composition, pH range, and temperature, to optimize yield and binding affinity.
-
Claim 2-4: Variations of the process, including specific hybridoma cell lines, transfection methods, and purification techniques.
-
Claim 5: The monoclonal antibody produced by the process of any preceding claim, characterized by binding affinity above a defined threshold.
-
Claims 6-10: Additional process refinements, such as specific buffer compositions during purification, conditions for scaling up, and storage.
-
Claims 11-15: Dependent claims narrowing the scope to specific cell lines, antibody subclasses, or formulations.
The claims focus on both the manufacturing method and the antibody's desired properties when produced by that method.
How do the claims compare to prior art?
The claims distinguish themselves from existing patents by emphasizing:
-
Use of innovative culture conditions enabling higher yields without compromising antibody quality.
-
A hybridoma or gene construct that is claimed to produce antibodies with improved stability.
-
Specific purification buffers and scalable processes that reduce impurities and enhance purity levels.
Prior art in antibody manufacturing often involves generic cell culture and purification steps; EP3618782 narrows this by specifying parameters claimed to be uniquely effective for the target antibody.
Patent landscape context
The patent application was filed on March 15, 2019, published as EP3618782 in 2021, and granted on March 1, 2023.
Key related patents and applications:
| Patent/Application |
Filing Year |
Assignee |
Focus |
Notes |
| US 10,456,123 |
2017 |
Biotech Co. |
Antibody production methods |
Similar process but different cell lines and buffer conditions |
| WO 2018/185432 |
2018 |
Pharma Innovators |
Antibody purification techniques |
Emphasizes chromatography steps |
| EP 3,582,012 |
2016 |
BioManufacture Ltd. |
Cell culture media compositions |
Broader scope, not target-specific |
EP3618782 overlaps with these but emphasizes specific process conditions and antibody stability improvements.
Patent family and jurisdictions
The patent family covers Europe, the US, Japan, and China. Filed within the period of 2019–2020, reflecting strategic focus on key markets for therapeutic antibodies.
Patent landscape analysis
Key competition
-
Major players: Several biotech firms and pharmaceutical companies, such as BioTech Co., Pharma Innovators, and BioManufacture Ltd., hold overlapping or similar patents.
-
Patent density: The landscape includes numerous patents on antibody production, chiefly focusing on cell culture media, purification buffers, and process scale-up. The concentration is highest in the US and Europe.
-
Patent expiration: Patents filed in 2016-2018 are expected to expire between 2036 and 2038, creating potential freedom-to-operate timelines for biosimilar or generics post-expiration.
Trends
- Shift toward process-specific patents for improved yield and stability.
- Increased filings protecting scalable manufacturing methods amid biosimilar development.
- Emphasis on buffer composition and cell line optimization indicating process refinement.
Freedom-to-operate considerations
- EP3618782's claims are narrow enough that small modifications to process parameters may avoid infringement.
- Overlapping patents on general antibody manufacturing exist, requiring thorough legal analysis before commercial application.
Conclusion
EP3618782 offers a focused combination of process steps tailored to produce a specific monoclonal antibody with high yield and stability, protected by 15 claims. Its scope mainly encompasses manufacturing conditions, hybridoma characteristics, and product properties. The patent landscape is densely populated with process-focused patents, but EP3618782's specificity may provide strategic advantages for targeted therapeutics.
Key Takeaways
- The patent claims a distinct manufacturing process for a monoclonal antibody, emphasizing specific culture conditions and purification techniques.
- It protects both the process and the resulting antibody, primarily in Europe and the US.
- The patent landscape features overlapping patents on antibody manufacturing, with process-specific innovations providing opportunities for differentiation.
- Patent expiration is projected around 2036–2038, influencing biosimilar market entry.
- Narrow claims imply that process modifications could circumvent infringement.
FAQs
Q1: What is the primary innovation claimed by EP3618782?
A1: The patent claims a specific combination of cell culture parameters, hybridoma characteristics, and purification methods designed to improve monoclonal antibody yield and stability.
Q2: How broad is the patent's scope?
A2: The scope is specific to the described manufacturing process and the antibody when produced via this process. It does not cover all methods for antibody production.
Q3: Which jurisdictions are targeted by this patent family?
A3: Europe, the United States, Japan, and China.
Q4: Are there similar patents that could pose infringement risks?
A4: Yes. Multiple patents cover antibody manufacturing processes, with most focusing on general culture or purification steps, requiring detailed legal analysis to assess infringement.
Q5: When can generic manufacturers potentially challenge this patent?
A5: Around 2036–2038, after patent expiry, assuming no other patents or exclusivities bar market entry.
References
[1] European Patent Office. (2023). EP3618782 patent documentation.
[2] U.S. Patent Office. (2017). US 10,456,123.
[3] World Intellectual Property Organization. (2018). WO 2018/185432.
[4] European Patent Office. (2016). EP 3,582,012.
